Abrysvo Or Arexvy Global Market Opportunities And Strategies To 2034
상품코드:1895279
리서치사:The Business Research Company
발행일:2025년 12월
페이지 정보:영문 246 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 아브리스보 또는 아렉스비 시장은 2024년에 약 15억 4,560만 달러 규모에 달했습니다. 2019년 이후, CAGR은 -39.36%로 감소하고 있습니다. 이 시장은 2024년 15억 4,560만 달러에서 2029년에는 13억 7,989만 달러로, 연간 -2.24%로 축소할 것으로 예측됩니다. 향후 2029년부터 CAGR 4.97%로 성장하며, 2034년에는 17억 5,834만 달러에 달할 전망입니다.
애브리스보/알렉스비 시장은 호흡기세포융합바이러스(RSV)에 의한 하기도 질환을 예방하기 위한 백신에 초점을 맞춘 예방접종 산업의 한 분야를 말합니다. 이 시장에는 화이자가 개발한 아브리스보와 GSK가 개발한 알렉스비라는 두 가지 주요 RSV 백신의 판매 및 투여가 포함되며, 각각 RSV 감염 위험이 높은 특정 집단을 대상으로 하고 있습니다.
애브리스보 또는 알렉스비 시장은 60세 이상 성인, 영아 보호 목적의 임산부, 심각한 RSV 감염 위험이 높은 18-59세 성인에게 사용되는 제품으로 인한 매출으로 구성되어 있습니다.
정부의 지원적 보건 정책
과거 애브리스보 또는 알렉스비 시장은 정부의 지원적인 보건 정책에 의해 주도되어 왔습니다. 정책 입안자들과 보건 당국은 호흡기세포융합바이러스(RSV)의 공중보건 및 경제적 부담, 특히 영유아와 노인의 경우, 호흡기세포융합바이러스(RSV)의 예방이 점점 더 우선순위가 되어가고 있습니다. 각국 정부는 RSV 백신을 국가 예방접종 프로그램에 포함시킴으로써 집단 보호 강화, 입원 환자 수 감소, 의료 시스템 부담 경감을 목표로 하고 있습니다. 예를 들어 호주의 비영리단체인 '면역연합'에 따르면 2024년에는 호주에서 역대 최다인 17만 5,786건의 RSV 사례가 보고될 것으로 예측됩니다. 이에 따라 정부는 2025년 2월 3일부터 임신부 백신 접종을 통해 영아를 보호하기 위해 화이자의 아브리즈보를 국가예방접종프로그램(NIP)에 추가한다고 발표했습니다. 이번 조치는 생후 6개월 미만의 영아에게 RSV가 미치는 영향을 강조하는 의료 전문가와 예방접종 연합의 지지가 높아짐에 따라 시행되었습니다. 이러한 정부 주도의 정책은 규제적, 재정적 측면에서 유리한 환경을 조성하여 아브리즈보와 알렉스비의 도입을 직접적으로 가속화하고 있습니다. 따라서 애브리스보 또는 알렉스비 시장은 주로 정부의 지원적인 보건정책에 의해 주도된 시장이라고 할 수 있습니다.
영유아 예방접종률 향상을 위한 임산부용 백신의 국제 사전 인증 획득
백신 시장의 주요 기업은 호흡기세포융합바이러스(RSV) 감염 위험이 높은 생후 6개월까지의 영아를 보호하기 위해 임산부 예방접종 전략에 집중하고 있습니다. 이러한 혁신은 영유아의 건강 상태 개선, 입원율 감소, 선진국과 자원이 부족한 환경 모두에서 예방 솔루션에 대한 전 세계 접근성 확대에 중점을 두고 있습니다. 예를 들어 2025년 3월, 혁신적인 의약품과 백신을 전문으로 하는 미국 기반 세계 제약사 화이자가 개발한 임산부용 RSV 백신 '아브리즈보'가 세계보건기구(WHO)의 사전 승인을 획득했습니다. 아브리즈보는 임신 중 모체에서 태아로 항체를 전달하여 태아를 보호하고, 생후 초기에 심각한 RSV 관련 질환의 위험을 감소시키도록 설계되었습니다. 화이자는 이번 WHO의 사전 승인을 통해 유엔기구를 통한 광범위한 조달 촉진, 각국의 예방접종 프로그램에 대한 신속한 통합, 그리고 세계 시장에서 생명을 구하는 RSV 예방책에 대한 접근성 확대를 목표로 하고 있습니다.
애브리스보(알렉스비) 세계 시장은 고도로 집중되어 있으며, 두 개의 대기업이 시장을 운영하고 있습니다. 2024년 기준, 주요 경쟁사 2곳이 전체 시장의 100%를 점유하고 있습니다.
목차
제1장 개요
아브리스보 또는 아렉스비 : 시장의 매력과 거시경제 환경
제2장 목차
제3장 표 리스트
제4장 도표 리스트
제5장 리포트 구성
제6장 시장의 특징
일반적인 시장의 정의
개요
아브리스보 또는 아렉스비 시장 정의와 세분화
임상 적응증별 시장 세분화
호흡기세포융합바이러스(RSV) 예방
유아 보호
연령층별 시장 세분화
성인(18-59세)
고령자(60세 이상)
임산부(임신 32-36주)
유통 채널별 시장 세분화
병원 및 헬스케어 프로바이더
정부/공중위생 프로그램
기타 유통 채널
제7장 주요 시장 동향
임산부용 백신의 국제적인 사전 인증에 의한 유아 예방 접종률의 향상
성인 RSV 백신의 규제 확대에 의한 전 연령층에 대한 보호 범위의 확대
고리스크 성인 집단에서 RSV 백신의 채택 확대
제8장 세계의 아브리스보 또는 아렉스비 성장 분석 및 전략적 분석 프레임워크
세계의 아브리스보 또는 아렉스비 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종사용자(B2B) 시장 분석
헬스케어 프로바이더
임산부
고리스크 성인
세계의 아브리스보 또는 아렉스비 시장 성장률 분석
시장 성장 실적, 2019-2024
시장 성장 촉진요인 2019-2024
시장 성장 억제요인 2019-2024
시장 성장 예측, 2024-2029, 2034F
시장 성장 촉진요인 2024-2029
시장 성장 억제요인 2024-2029
세계의 아브리스보 또는 아렉스비 : TAM(Total Addressable Market)
제9장 세계의 아브리스보 또는 아렉스비 세계 시장 : 세분화
세계의 아브리스보 또는 아렉스비 시장 : 질환별, 실적과 예측, 2023-2024, 2029F, 2034F
세계의 아브리스보 또는 아렉스비 시장 : 연령층별, 실적과 예측, 2023-2024, 2029F, 2034F
세계의 아브리스보 또는 아렉스비 시장 : 유통 채널별, 실적과 예측, 2023-2024, 2029F, 2034F
제10장 아브리스보 또는 아렉스비 시장 : 지역·국가별 분석
세계의 아브리스보 또는 아렉스비 시장 : 지역별, 실적과 예측, 2023-2024, 2029F, 2034F
세계의 아브리스보 또는 아렉스비 시장 : 국가별, 실적과 예측, 2023-2024, 2029F, 2034F
제11장 아시아태평양 시장
제12장 서유럽 시장
제13장 동유럽 시장
제14장 북미 시장
제15장 남미 시장
제16장 중동 시장
제17장 아프리카 시장
제18장 경쟁 구도와 기업 개요
기업 개요
Glaxo SmithKline(GSK) Plc
Pfizer Inc.
제19장 경쟁 벤치마킹
제20장 경쟁 대시보드
제21장 기회와 전략
세계의 아브리스보 또는 아렉스비 시장 2029 : 새로운 기회를 제공하는 국가
세계의 아브리스보 또는 아렉스비 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제22장 아브리스보 또는 아렉스비 시장 : 결론과 제안
결론
제안
제품
장소
가격
프로모션
사람들
제23장 부록
KSA
영문 목차
영문목차
The Abrysvo / Arexvy market refers to the segment of the immunization industry focused on vaccines designed to prevent lower respiratory tract disease caused by respiratory syncytial virus (RSV). This market encompasses the sales and administration of two leading RSV vaccines-Abrysvo, developed by Pfizer, and Arexvy, developed by GSK each targeting specific populations vulnerable to RSV infections.
The Abrysvo or Arexvy market consists of revenues generated by entities that are used in adults aged 60 years and older, pregnant individuals to confer infant protection, and adults aged 18-59 years who are at increased risk for severe RSV illness.
The global Abrysvo or Arexvy market reached a value of nearly $1,545.60 million in 2024, having declined at a compound annual growth rate (CAGR) of -39.36% since 2019. The market is expected to decline from $1,545.60 million in 2024 to $1,379.89 million in 2029 at a rate of -2.24%. The market is then expected to grow at a CAGR of 4.97% from 2029 and reach $1,758.34 million in 2034.
Supportive Government Health Policies
During the historic period, the abrysvo or arexvy market was driven by supportive government health policies. Policymakers and health authorities increasingly prioritized the prevention of respiratory syncytial virus (RSV) due to its substantial public health and economic burden, especially among infants and older adults. By integrating RSV vaccines into national immunization programs, governments aimed to strengthen population-level protection, reduce hospitalizations, and ease strain on healthcare systems. For instance, on February 2025, according to the Immunisation Coalition, an Australian not-for-profit organization, in the year 2024, Australia reported a record 175,786 RSV cases, the highest number ever recorded in the country. In response, the government announced the addition of Pfizer's Abrysvo to its National Immunization Program (NIP), beginning February 3, 2025, to protect infants via maternal vaccination during pregnancy. This move followed growing advocacy from medical experts and immunization coalitions highlighting RSV's impact on infants in their first six months of life. Such government-driven measures created a favorable regulatory and funding environment, directly accelerating the adoption of Abrysvo and Arexvy. Therefore, the abrysvo or arexvy market was mainly driven by supportive government health policies.
Global Prequalification Of Maternal Vaccines To Enhance Infant Immunization Coverage
Major companies in the vaccine market are focusing on maternal immunization strategies to protect infants during the first six months of life, a period of heightened vulnerability to respiratory syncytial virus (RSV). These innovations emphasize improving infant health outcomes, reducing hospitalization rates, and expanding global access to preventive solutions in both developed and low-resource settings. For instance, in March 2025, the World Health Organization (WHO) prequalified Abrysvo, a maternal RSV vaccine developed by Pfizer Inc., a US-based global pharmaceutical company specializing in innovative medicines and vaccines. Abrysvo is designed to provide protection to infants by transferring antibodies from mother to child during pregnancy, thereby reducing the risk of severe RSV-related illness in early infancy. By securing WHO prequalification, Pfizer aims to facilitate broader procurement through United Nations agencies, accelerate integration into national immunization programs, and expand access to life-saving RSV protection across global markets.
The global Abrysvo or Arexvy market is highly concentrated, with two large players operating in the market. The major 2 competitors in the market made up to 100% of the total market in 2024.
Abrysvo Or Arexvy Global Market Opportunities And Strategies To 2034 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global abrysvo or arexvy market as it emerges from the COVID-19 shut down.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 11 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Where is the largest and fastest-growing market for abrysvo or arexvy? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The abrysvo or arexvy market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider abrysvo or arexvy market; and compares it with other markets.
The report covers the following chapters
Introduction And Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by clinical indication, by age group and by end user.
Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Growth Analysis And Strategic Analysis Framework- Analysis on PESTEL, end use industries, market growth rate, global historic (2019-2024) and forecast (2024-2029, 2034F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
Regional And Country Analysis - Historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison by region and country.
Market Segmentation - Contains the market values (2019-2024) (2024-2029, 2034F) and analysis for each segment by clinical indication, by age group and by end user in the market. Historic (2019-2024) and forecast (2024-2029) and (2029-2034) market values and growth and market share comparison by region market.
Regional Market Size And Growth - Regional market size (2024), historic (2019-2024) and forecast (2024-2029, 2034F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Other Major And Innovative Companies - Details on the company profiles of other major and innovative companies in the market.
Competitive Dashboard Briefs on competitive dashboard of major players.
Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
Key Mergers And Acquisitions- Information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions, which have shaped the market in recent years.
Recent Developments- Information on recent developments in the market covered in the report.
Market Opportinities And Strategies - Contains information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
Conclusions And Recommendations- This section includes recommendations for abrysvo or arexvy providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
8.6 Global Abrysvo Or Arexvy Total Addressable Market (TAM)
9 Global Abrysvo Or Arexvy Market Segmentation
9.1 Global Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
9.2 Global Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
9.3 Global Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
10 Abrysvo Or Arexvy Market, Regional and Country Analysis
10.1 Global Abrysvo Or Arexvy Market, By Region, Historic and Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
10.2 Global Abrysvo Or Arexvy Market, By Country, Historic and Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11 Asia-Pacific Market
11.1 Summary
11.2 Market Overview
11.2.1 Region Information
11.2.2 Market Information
11.2.3 Background Information
11.2.4 Government Initiatives
11.2.5 Regulations
11.2.6 Regulatory Bodies
11.2.7 Major Associations
11.2.8 Taxes Levied
11.2.9 Corporate Tax Structure
11.2.10 Investments
11.2.11 Major Companies
11.3 Asia-Pacific Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.4 Asia-Pacific Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.5 Asia-Pacific Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.6 Asia-Pacific Abrysvo Or Arexvy Market: Country Analysis
11.7 China Market
11.8 Summary
11.9 Market Overview
11.9.1 Country Information
11.9.2 Market Information
11.9.3 Background Information
11.9.4 Government Initiatives
11.9.5 Regulations
11.9.6 Regulatory Bodies
11.9.7 Major Associations
11.9.8 Taxes Levied
11.9.9 Corporate Tax Structure
11.9.10 Investments
11.9.11 Major Companies
11.10 China Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.11 China Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.12 China Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.13 India Market
11.14 India Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.15 India Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.16 India Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.17 Japan Market
11.18 Summary
11.19 Market Overview
11.19.1 Country Information
11.19.2 Market Information
11.19.3 Background Information
11.19.4 Government Initiatives
11.19.5 Regulations
11.19.6 Regulatory Bodies
11.19.7 Major Associations
11.19.8 Taxes Levied
11.19.9 Corporate Tax Structure
11.19.10 Investments
11.19.11 Major Companies
11.20 Japan Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.21 Japan Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.22 Japan Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.23 South Korea Market
11.24 Summary
11.25 Market Overview
11.25.1 Country Information
11.25.2 Market Information
11.25.3 Background Information
11.25.4 Government Initiatives
11.25.5 Regulations
11.25.6 Regulatory Bodies
11.25.7 Major Associations
11.25.8 Taxes Levied
11.25.9 Corporate Tax Structure
11.25.10 Investments
11.25.11 Major Companies
11.26 South Korea Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.27 South Korea Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.28 South Korea Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.29 Australia Market
11.30 Australia Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.31 Australia Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
11.32 Australia Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
12 Western Europe Market
12.1 Summary
12.2 Market Overview
12.2.1 Region Information
12.2.2 Market Information
12.2.3 Background Information
12.2.4 Government Initiatives
12.2.5 Regulations
12.2.6 Regulatory Bodies
12.2.7 Major Associations
12.2.8 Taxes Levied
12.2.9 Corporate tax structure
12.2.10 Investments
12.2.11 Major Companies
12.3 Western Europe Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
12.4 Western Europe Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
12.5 Western Europe Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
12.6 Western Europe Abrysvo Or Arexvy Market: Country Analysis
12.7 UK Market
12.8 UK Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
12.9 UK Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
12.10 UK Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
12.11 Germany Market
12.12 Germany Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
12.13 Germany Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
12.14 Germany Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
12.15 France Market
12.16 France Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
12.17 France Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
12.18 France Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
13 Eastern Europe Market
13.1 Summary
13.2 Market Overview
13.2.1 Region Information
13.2.2 Market Information
13.2.3 Background Information
13.2.4 Government Initiatives
13.2.5 Regulations
13.2.6 Regulatory Bodies
13.2.7 Major Associations
13.2.8 Taxes Levied
13.2.9 Corporate Tax Structure
13.2.10 Major companies
13.3 Eastern Europe Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
13.4 Eastern Europe Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
13.5 Eastern Europe Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
14 North America Market
14.1 Summary
14.2 Market Overview
14.2.1 Region Information
14.2.2 Market Information
14.2.3 Background Information
14.2.4 Government Initiatives
14.2.5 Regulations
14.2.6 Regulatory Bodies
14.2.7 Major Associations
14.2.8 Taxes Levied
14.2.9 Corporate Tax Structure
14.2.10 Investments
14.2.11 Major Companies
14.3 North America Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
14.4 North America Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
14.5 North America Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
14.6 North America Abrysvo Or Arexvy Market: Country Analysis
14.7 USA Market
14.8 Summary
14.9 Market Overview
14.9.1 Country Information
14.9.2 Market Information
14.9.3 Background Information
14.9.4 Government Initiatives
14.9.5 Regulations
14.9.6 Regulatory Bodies
14.9.7 Major Associations
14.9.8 Taxes Levied
14.9.9 Corporate Tax Structure
14.9.10 Investments
14.9.11 Major Companies
14.10 USA Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
14.11 USA Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
14.12 USA Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
14.13 Canada Market
14.14 Summary
14.15 Market Overview
14.15.1 Country Information
14.15.2 Market Information
14.15.3 Background Information
14.15.4 Government Initiatives
14.15.5 Regulations
14.15.6 Regulatory Bodies
14.15.7 Major Associations
14.15.8 Taxes Levied
14.15.9 Corporate Tax Structure
14.15.10 Investments
14.15.11 Major Companies
14.16 Canada Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
14.17 Canada Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
14.18 Canada Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
15 South America Market
15.1 Summary
15.2 Market Overview
15.2.1 Region Information
15.2.2 Market Information
15.2.3 Background Information
15.2.4 Government Initiatives
15.2.5 Regulations
15.2.6 Regulatory Bodies
15.2.7 Major Associations
15.2.8 Taxes Levied
15.2.9 Corporate Tax Structure
15.2.10 Investments
15.2.11 Major Companies
15.3 South America Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
15.4 South America Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
15.5 South America Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
16 Middle East Market
16.1 Summary
16.2 Market Overview
16.2.1 Region Information
16.2.2 Market Information
16.2.3 Background Information
16.2.4 Government Initiatives
16.2.5 Regulations
16.2.6 Regulatory Bodies
16.2.7 Major Associations
16.2.8 Taxes Levied
16.2.9 Corporate Tax Structure
16.2.10 Major Companies
16.3 Middle East Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
16.4 Middle East Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
16.5 Middle East Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
17 Africa Market
17.1 Summary
17.2 Market Overview
17.2.1 Region Information
17.2.2 Market Information
17.2.3 Background Information
17.2.4 Government Initiatives
17.2.5 Regulations
17.2.6 Regulatory Bodies
17.2.7 Major Associations
17.2.8 Taxes Levied
17.2.9 Corporate Tax Structure
17.2.10 Major Companies
17.3 Africa Abrysvo Or Arexvy Market, Segmentation By Clinical Indication, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
17.4 Africa Abrysvo Or Arexvy Market, Segmentation By Age Group, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
17.5 Africa Abrysvo Or Arexvy Market, Segmentation By Distribution Channel, Historic And Forecast, 2023 - 2024, 2029F, 2034F, Value ($ Million)
18 Competitive Landscape And Company Profiles
18.1 Company Profiles
18.2 Glaxo SmithKline (GSK) Plc
18.2.1 Company Overview
18.2.2 Products And Services
18.2.3 Financial Overview
18.3 Pfizer Inc.
18.3.1 Company Overview
18.3.2 Products And Services
18.3.3 Business Strategy
18.3.4 Financial Overview
19 Competitive Benchmarking
20 Competitive Dashboard
21 Opportunities And Strategies
21.1 Global Abrysvo Or Arexvy Market In 2029 - Countries Offering Most New Opportunities
21.2 Global Abrysvo Or Arexvy Market In 2029 - Growth Strategies
21.2.1 Market Trend Based Strategies
21.2.2 Competitor Strategies
22 Abrysvo Or Arexvy Market, Conclusions And Recommendations
